CA3032810A1 - Methodes de preparation de liposomes - Google Patents

Methodes de preparation de liposomes Download PDF

Info

Publication number
CA3032810A1
CA3032810A1 CA3032810A CA3032810A CA3032810A1 CA 3032810 A1 CA3032810 A1 CA 3032810A1 CA 3032810 A CA3032810 A CA 3032810A CA 3032810 A CA3032810 A CA 3032810A CA 3032810 A1 CA3032810 A1 CA 3032810A1
Authority
CA
Canada
Prior art keywords
antibody
liposomes
liposome
encapsulated
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3032810A
Other languages
English (en)
Inventor
Indu Javeri
Kaliappanadar Nellaiappan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curirx Inc
Original Assignee
Curirx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/226,364 external-priority patent/US10143652B2/en
Application filed by Curirx Inc filed Critical Curirx Inc
Publication of CA3032810A1 publication Critical patent/CA3032810A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des méthodes de préparation de liposomes et les utilisations de ces derniers. Dans certains modes de réalisation, des liposomes sont préparés sans recours à la chaleur, à des solvants organiques, à des protéines et/ou à des sels inorganiques. Dans certains modes de réalisation, la préparation de liposomes contient un ou plusieurs agents actifs. Dans certains modes de réalisation, les préparations de liposomes sont utilisées dans le traitement de maladies ou de troubles.
CA3032810A 2016-08-02 2017-08-01 Methodes de preparation de liposomes Pending CA3032810A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/226,364 2016-08-02
US15/226,364 US10143652B2 (en) 2009-09-23 2016-08-02 Methods for the preparation of liposomes
PCT/US2017/044865 WO2018026794A1 (fr) 2016-08-02 2017-08-01 Méthodes de préparation de liposomes

Publications (1)

Publication Number Publication Date
CA3032810A1 true CA3032810A1 (fr) 2018-02-08

Family

ID=61073551

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3032810A Pending CA3032810A1 (fr) 2016-08-02 2017-08-01 Methodes de preparation de liposomes

Country Status (5)

Country Link
EP (1) EP3493790A4 (fr)
JP (1) JP7019201B2 (fr)
CN (1) CN109562067A (fr)
CA (1) CA3032810A1 (fr)
WO (1) WO2018026794A1 (fr)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857319A (en) * 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
WO1992011864A1 (fr) * 1991-01-11 1992-07-23 Cryopharm Corporation Procede de detection de types anticorpaux en circulation a l'aide de cellules ou matieres cellulaires sechees ou lyophilisees
US6156337A (en) * 1994-07-08 2000-12-05 Opperbas Holding B.V. Method for high loading of vesicles with biopolymeric substances
WO2002072011A2 (fr) * 2001-03-08 2002-09-19 Targesome, Inc. Agents therapeutiques et d'imagerie stabilises
US8980310B2 (en) * 2002-12-31 2015-03-17 Bharat Serums and Vaccines, Ltd. Non-pegylated long-circulating liposomes
ATE476964T1 (de) * 2003-06-04 2010-08-15 Univ Georgetown Verfahren zur verbesserung der stabilität und der haltbarkeit von liposom-komplexen
DE602004019546D1 (de) * 2003-08-26 2009-04-02 Smithkline Beecham Corp Heterofunktionelle copolymere von glycerol und polyethylenglykol, ihre konjugate und zusammensetzungen
JP2007509040A (ja) * 2003-10-11 2007-04-12 イネックス ファーマシューティカルズ コーポレイション 先天性免疫及び抗体依存性細胞傷害を強化するための方法及び組成物
CA2582937A1 (fr) * 2004-10-06 2006-04-13 Bc Cancer Agency Formulation de constructions d'anticorps multivalentes et utilisation de ces constructions pour le traitement du cancer
WO2006050327A2 (fr) * 2004-10-28 2006-05-11 Alza Corporation Formulations de liposomes lyophilises et methode associee
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
CA2605560A1 (fr) * 2005-04-22 2006-11-02 Kristen Hjortsvang Composition d'immunoliposomes destinee au ciblage d'un recepteur des cellules her2
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
WO2007127272A2 (fr) * 2006-04-24 2007-11-08 The Cbr Institute For Biomedical Research Méthode de production d'immunoliposomes et compositions les incluant
US20090162425A1 (en) * 2007-09-19 2009-06-25 University Of Tennessee Research Foundation Methods and compositions for inhibiting undesirable cellular proliferation by targeted liposome delivery of active agents
EP2219587A4 (fr) * 2007-11-14 2012-11-21 Univ California Lipides amphiphiles modifiés par un stérol
JP2009203174A (ja) * 2008-02-26 2009-09-10 Hokkaido Univ タンパク質−リポソーム複合体を含有するイオントフォレーシス用組成物
EP2480208A1 (fr) * 2009-09-23 2012-08-01 Indu Javeri Méthodes de préparation de liposomes
CN102100916A (zh) * 2009-12-22 2011-06-22 上海抗体药物国家工程研究中心有限公司 一种冻干脂质体、其制备方法和用途
US20120231066A1 (en) * 2011-01-24 2012-09-13 Henry John Smith Multi-drug liposomes to treat tumors
US20140112979A1 (en) * 2011-07-04 2014-04-24 Statens Serum Institut Methods for producing liposomes
CA2858336A1 (fr) * 2012-01-01 2013-07-04 Qbi Enterprises Ltd. Particules ciblant endo180 pour l'administration selective d'agents therapeutiques et diagnostiques
MY176838A (en) * 2012-08-16 2020-08-24 Ipierian Inc Methods of treating a tauopathy
JP2014062084A (ja) * 2012-09-19 2014-04-10 Georgetown Univ 標的化されたリポソーム

Also Published As

Publication number Publication date
JP7019201B2 (ja) 2022-02-15
JP2019526619A (ja) 2019-09-19
EP3493790A4 (fr) 2020-03-25
CN109562067A (zh) 2019-04-02
EP3493790A1 (fr) 2019-06-12
WO2018026794A1 (fr) 2018-02-08

Similar Documents

Publication Publication Date Title
CA2781527C (fr) Methodes de preparation de liposomes
TWI355946B (en) Proliposomal and liposomal compositions of poorly
CA2704258C (fr) Nouveaux liposomes thermosensibles contenant des agents therapeutiques
RU2526114C2 (ru) Липосомы иринотекана или его солей, способ их получения
US20050238706A1 (en) Pharmaceutically active lipid based formulation of SN-38
US20110070294A1 (en) Methods for the Administration of Drugs Using Liposomes
JP5787905B2 (ja) 新規なリポソームを調製するための方法および装置
AU780194B2 (en) Method of regulating leakage of drug encapsulated in liposomes
US20060030578A1 (en) Pharmaceutically active lipid based formulation of irinotecan
JP2008518925A (ja) リポソーム製剤の製造プロセス
US10143652B2 (en) Methods for the preparation of liposomes
WO2006049307A1 (fr) Liposome et méthode d’injection d’une substance dans une cellule à l’aide dudit liposome
US20170340563A1 (en) Methods for the Preparation of Liposomes Comprising Drugs
WO2018209342A1 (fr) Procédés de préparation de liposomes comprenant des médicaments
CA3032810A1 (fr) Methodes de preparation de liposomes
KR101846090B1 (ko) 독소루비신 함유 페길화된 리포좀 제제의 제조방법
Djekic Liposomes: Properties and therapeutic applications
JP2013534523A (ja) 溶解度が向上した難溶性トリサイクリック誘導体の薬学的組成物
JP2012236772A (ja) スピカマイシン誘導体を有するリポソーム製剤
PL197938B1 (pl) Liposomowy preparat zawierający przeciwnowotworową substancję aktywną, sposób jego wytwarzania i zawierająca go kompozycja farmaceutyczna
PL197939B1 (pl) Liposomowy preparat zawierający przeciwnowotworową substancję aktywną, sposób jego wytwarzania i zawierająca go kompozycja farmaceutyczna

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220726

EEER Examination request

Effective date: 20220726

EEER Examination request

Effective date: 20220726

EEER Examination request

Effective date: 20220726

EEER Examination request

Effective date: 20220726